New Online Course — 2025

Lipoprotein(a):

A Practical Guide for Clinicians

1 in 5 of your patients has elevated Lp(a). Most have never been tested. This evidence-based online course gives you the confidence to test, interpret and act — from your next consultation.

8 modules
3–4 hours CPD
UK & USA guidance
Certificate issued
Enrol Now View Curriculum

What's included

Everything you need to use Lp(a) confidently in clinical practice

  • 8 video modules — watch at your own pace
  • Real clinical cases from practice
  • EAS 2022, ACC/AHA 2026, ESC 2025 guidelines
  • UK and US testing & treatment frameworks
  • 15-question end-of-course assessment
  • Certificate of completion
  • One-page clinical reference summary
  • Lifetime access to materials

Course Price

£79 / $99

One-time payment · Immediate access · Lifetime materials

Enrol Now

Why This Matters

The scale of what
we're missing.

1 in 5

adults have elevated Lp(a)

Approximately 1.4 billion people worldwide have Lp(a) levels high enough to meaningfully increase cardiovascular risk. In a list of 2,000 patients, that's approximately 400 people.

0.8%

of eligible US adults have been tested

Razavi et al, JACC Advances 2025: despite clear guideline recommendations, Lp(a) remains dramatically undertested — with significant disparities by ethnicity and education level.

2–3×

higher cardiovascular risk — often undetected

High Lp(a) can double or triple cardiovascular risk even when standard lipid panels look normal. Standard risk calculators may significantly underestimate risk in these patients.

"A patient with a perfect lipid panel can still be at triple the cardiovascular risk — because Lp(a) was never measured. This course gives you the tools to find it."

Course Curriculum

Eight modules. One goal:
Lp(a) in clinical practice.

01

Why Lipoprotein(a) Matters

The hidden risk factor — scale of the problem, why standard lipids miss it, and the clinical uncertainty we face daily. Opening case: identifying risk that was invisible.

02

What is Lp(a)? — Biology and Mechanisms

Structure explained from first principles. Three reasons Lp(a) increases cardiovascular risk: atherogenesis, oxidised phospholipids, and impaired fibrinolysis.

03

Who Should Be Tested?

Guideline-based testing framework covering all six high-yield clinical scenarios. When to repeat testing. UK and US access pathways. The equity gap in Lp(a) testing.

04

Interpreting Results

Units, thresholds, and clinical context. nmol/L vs mg/dL — the units problem explained. EAS three-tier framework. ESC 2025 risk reclassification. Case studies.

05

What to Do When Lp(a) is High

Treatment targets for UK/Europe and USA. ESC 2025 risk categories and LDL targets. HEART UK consensus. PCSK9 inhibitors and the Lp(a) advantage. ApoB monitoring.

06

Cascade Testing and Family Risk

47% concordance in first-degree relatives. Practical cascade testing framework. The aortic stenosis connection — evidence and clinical position. How to have the family conversation.

07

Future Therapies

RNA therapies and the Phase 3 trial landscape. Pelacarsen, olpasiran, zerlasiran, lepodisiran, muvalaplin. How much reduction is needed? What to do for patients now.

08

Key Takeaways for Clinical Practice

Five key points. Five questions for every Lp(a) patient. One-page clinical reference. The practice changes that matter most from day one.

Who This Course is For

Built for doctors
in clinical practice.

🩺

General Practitioners & Primary Care Physicians

UK GPs and US primary care doctors — the clinicians best placed to identify and act on Lp(a) early.

❤️

Cardiologists & Preventive Cardiologists

Deepen your practical framework for integrating Lp(a) into cardiovascular risk assessment and management.

🔬

Internists & General Physicians

For any generalist managing cardiovascular risk who wants to move beyond standard lipid panels.

🌍

UK and International Clinicians

Dual framework covers ESC/EAS 2025 (UK/Europe) and ACC/AHA 2026 (USA) — practical for both settings.

Evidence Base

EAS 2022

Kronenberg et al — European Heart Journal. Primary source for testing thresholds and risk framework.

ESC 2025

Focused update — Lp(a) formally listed as Box 1 risk modifier. Risk reclassification guidance.

ACC/AHA 2026

Blumenthal et al, JACC. Class 1 cascade testing. US risk-enhancing factor framework.

HEART UK

Consensus statement — UK-specific Lp(a) management including non-HDL targets and apheresis criteria.

ODYSSEY 2025

Tsimikas et al — alirocumab, OxPL-apoB, and MACE benefit at highest Lp(a) levels.

Source Material

Built on the best
available evidence.

Mayo Clinic 2025

Awad et al — Lp(a) variability study, 11,669 patients. Informs retesting guidance for borderline patients and women on statins.

JAMA Cardiology 2023

Reeskamp et al — cascade testing concordance. 47% of first-degree relatives affected. NNS of 2.1. Underpins Module 6 cascade framework.

JACC Advances 2025

Razavi et al — only 0.8% of eligible US adults tested. 32% lower testing odds in Black Americans. Equity data in Module 3.

J Lipid Atheroscler 2025

Yao et al — oxidised Lp(a) and impaired fibrinolysis. Concentration- and oxidation-dependent effects. Mechanisms Module 2.

Dr Lucy Hooper — Private GP and Medical Educator

About the Author

Dr Lucy Hooper

I'm a GP and co-founder of Coyne Medical — one of London's leading private GP and health screening clinics. I've spent the last fifteen years practising exactly the kind of comprehensive cardiovascular risk assessment that this course teaches.

I hold a BSc in Cardiovascular Science and an MA in Healthcare Law and Ethics. I'm a member of both the British Society of Genetic Medicine and the European Atherosclerosis Society. Lp(a) is not a side interest for me — it's central to how I assess cardiovascular risk in every patient who comes to my clinic.

I built this course because I kept seeing patients whose Lp(a) had never been measured — patients with premature heart disease, unexplained events, strong family histories — whose risk had been missed for years. This course is my attempt to give other clinicians the training I wish had existed when I started.

BSc Cardiovascular Science
Undergraduate degree
MA Healthcare Law & Ethics
Postgraduate
BSGM Member
British Society of Genetic Medicine
EAS Member
European Atherosclerosis Society

"Clear, practical, evidence-based. The kind of clinical education that changes how you practise."

"I've been practising for twelve years and no-one ever taught me this at medical school or in training. The module on interpreting results alone was worth it — I finally understand the units problem."

GP, London

Early course participant

"The case studies made it real. I went back to clinic the next day and ordered Lp(a) on three patients I'd been uncertain about. All three came back elevated. This course changed how I practise."

Internist, USA

Early course participant

"The guideline framework is excellent — having ESC/EAS, HEART UK and ACC/AHA in one place, properly integrated, is something I've been looking for. Highly recommended for any clinician managing cardiovascular risk."

Cardiologist, UK

Early course participant

Common Questions

Frequently asked
questions.

Is this course accredited for CME/CPD?

The course is not currently formally accredited for CME credit. A certificate of completion is issued on passing the end-of-course assessment (80% pass mark). Many clinicians use this for personal CPD portfolios.

How long does the course take?

The course takes approximately 3 to 4 hours to complete across all 8 modules. All content is available immediately on enrolment and can be completed at your own pace.

Is this relevant for UK doctors and US doctors?

Yes — the course is built for both. Modules explicitly cover ESC/EAS 2025 and HEART UK guidelines for UK/European practice, and ACC/AHA 2026 for US practice. Testing access pathways cover both systems.

What do I need to take this course?

This course is designed for qualified healthcare professionals — GPs, cardiologists, internists, and general physicians. No prior knowledge of Lp(a) is required. All biology is explained from first principles.

How do I receive my certificate?

On completing the 15-question end-of-course assessment with a score of 80% or above, a PDF certificate of completion is automatically emailed to you. You may retake the assessment if needed.

Can I access the materials after completing the course?

Yes — you have lifetime access to all course materials including the one-page clinical reference summary, which is designed to be kept and used in practice.

The patient with undetected Lp(a) is in your waiting room right now.

This course is the training that gives you the confidence to find them, understand their risk, and act appropriately — from your next consultation. Join doctors across the UK and US who are already practising preventive medicine the way it should be done.

Enrol Now — £79 / $99

£79 / $99 · One-time payment · Immediate access · Lifetime materials · Certificate on completion · For qualified healthcare professionals only